Given that the current immunotherapy (PD-L1 inhibitor avelumab) failed in a phase I clinical trial for ACC [14], identification of novel immune markers and therapeutic targets in ACC is urgently needed. This evidence concerns the gene CD274 and adrenal cortex carcinoma.